We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
+32.15%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$2.4B
AUM Growth
+$519M
Cap. Flow
+$109M
Cap. Flow %
4.53%
Top 10 Hldgs %
68.89%
Holding
38
New
2
Increased
14
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
AIMT
Aimmune Therapeutics
AIMT
+$55.6M
2
VNDA icon
Vanda Pharmaceuticals
VNDA
+$20.5M
3
IMMU
Immunomedics Inc
IMMU
+$19.3M
4
KLDO
Kaleido Biosciences, Inc. Common Stock
KLDO
+$11.9M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$7.58M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$23.3M
2
SHPG
Shire pic
SHPG
+$8.34M
3
MLNT
Melinta Therapeutics, Inc. Common Stock
MLNT
+$5

Sector Composition

Rank Sector Weight
1 Healthcare 89.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMRN icon
1
BioMarin Pharmaceuticals
BMRN
$13.3B
$235M 9.79%
2,641,485
+81,752
+3% +$7.58M
INSM icon
2
Insmed
INSM
$29B
$222M 9.28%
7,653,617
– –
ABMD
3
DELISTED
Abiomed Inc
ABMD
$200M 8.32%
698,654
+9,104
+1% +$3.03M
UTHR icon
4
United Therapeutics
UTHR
$22.6B
$192M 7.99%
1,632,025
– –
ALXN
5
DELISTED
Alexion Pharmaceuticals
ALXN
$166M 6.93%
1,229,030
+24,702
+2% +$3.07M
STAA icon
6
STAAR Surgical
STAA
$1.25B
$144M 6.02%
4,218,902
+70,914
+2% +$2.51M
SAGE
7
DELISTED
Sage Therapeutics
SAGE
$136M 5.69%
857,681
+6,704
+0.8% +$971K
CLVS
8
DELISTED
Clovis Oncology, Inc.
CLVS
$130M 5.43%
5,239,304
– –
IMMU
9
DELISTED
Immunomedics Inc
IMMU
$123M 5.11%
6,381,555
+1,195,300
+23% +$19.3M
FOLD
10
DELISTED
Amicus Therapeutics
FOLD
$104M 4.32%
7,619,833
+218,512
+3% +$2.67M
VNDA icon
11
Vanda Pharmaceuticals
VNDA
$297M
$93M 3.88%
5,055,050
+899,380
+22% +$20.5M
WMGI
12
DELISTED
Wright Medical Group Inc
WMGI
$87.2M 3.64%
2,771,394
– –
EPZM
13
DELISTED
Epizyme, Inc
EPZM
$85.9M 3.58%
6,935,074
– –
AIMT
14
DELISTED
Aimmune Therapeutics
AIMT
$83.8M 3.5%
3,748,939
+2,361,350
+170% +$55.6M
ACAD icon
15
Acadia Pharmaceuticals
ACAD
$5.06B
$60.4M 2.52%
2,248,403
+222,340
+11% +$5.19M
ALGN icon
16
Align Technology
ALGN
$12.5B
$47M 1.96%
165,405
+8,582
+5% +$2.05M
PBYI icon
17
Puma Biotechnology
PBYI
$447M
$45.8M 1.91%
1,180,780
+20,880
+2% +$638K
AMAG
18
DELISTED
AMAG Pharmaceuticals
AMAG
$44.1M 1.84%
3,421,306
+40,800
+1% +$608K
KPTI icon
19
Karyopharm Therapeutics
KPTI
$44.6M
$30.7M 1.28%
350,818
+38,461
+12% +$4.26M
EXAS
20
DELISTED
Exact Sciences
EXAS
$27.3M 1.14%
314,889
– –
MNTA
21
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$26.8M 1.12%
1,841,613
– –
ALDR
22
DELISTED
Alder Biopharmaceuticals
ALDR
$25.4M 1.06%
1,861,630
– –
CELG
23
DELISTED
Celgene Corp
CELG
$25.1M 1.05%
266,333
-266,334
-50% -$23.3M
PRTA icon
24
Prothena Corp
PRTA
$450M
$13.4M 0.56%
1,108,510
– –
KLDO
25
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
$12.6M 0.52%
+866,666
New +$11.9M
1
2

Similar funds

RRA
Round Rock Advisors Wilton, Connecticut $654M AUM 22.95% 1-Year Est. Return
AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
CG
CFO4Life Group Coppell, Texas $656M AUM 17.88% 1-Year Est. Return
SCM
Stevens Capital Management Radnor, Pennsylvania $649M AUM 27.37% 1-Year Est. Return
GAMA
Graticule Asia Macro Advisors New York $649M AUM
PIM
Parker Investment Management Menlo Park, California $659M AUM 52.52% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return

Palo Alto Investors's Q1 2019 Portfolio in Review

As of Q1 2019, Palo Alto Investors held 38 positions worth $2.4B, up 28% from $1.88B the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Palo Alto Investors deployed $109M of net new capital in Q1 2019, opening 2 new positions and adding to 14 existing holdings. Its largest new stake was Kaleido Biosciences, Inc. Common Stock: 866,666 shares worth $12.6M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 91% a quarter earlier.

On the sell side, the largest reduction was Celgene Corp, an estimated $23.3M trimmed.

  • Palo Alto Investors's largest Q1 2019 buy was Kaleido Biosciences, Inc. Common Stock: 866,666 shares worth $12.6M.
  • Palo Alto Investors added most to Aimmune Therapeutics in Q1 2019, an estimated $55.6M increase.
  • Palo Alto Investors's biggest Q1 2019 reduction was Celgene Corp, cutting an estimated $23.3M.
  • Palo Alto Investors fully exited Shire pic in Q1 2019, selling an estimated $8.34M.
  • Palo Alto Investors's ten largest holdings make up 69% of its $2.4B portfolio in Q1 2019.
  • Palo Alto Investors opened 2 new positions and closed 1 in Q1 2019.
  • Palo Alto Investors's portfolio value rose 28% quarter-over-quarter to $2.4B.

Based on Palo Alto Investors's 13F filing for Q1 2019, filed 15 May 2019.